Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NCEH1 | Q6PIU2 | 7/20 | 0.55 |
| ▸ | RAB9A | P51151 | 2/20 | 0.53 |
| ▸ | TSHR | P16473 | 2/20 | 0.53 |
| ▸ | PKM | P14618 | 1/20 | 0.53 |
| ▸ | NPC1 | O15118 | 1/20 | 0.53 |
| ▸ | CES2 | O00748 | 1/20 | 0.47 |
| ▸ | BCHE | P06276 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10774367 | 0.86 | ACHE (0.51) | NCEH1RAB9ATSHRPKMNPC1 | |
| SCHEMBL16965115 | 0.82 | RAB9A (0.60) | NCEH1RAB9ATSHRPKMNPC1 | |
| SCHEMBL8434637 | 0.81 | CES2 (0.52) | TSHRCES2LMNA | |
| SCHEMBL11799252 | 0.81 | RAB9A (0.47) | NCEH1RAB9ATSHRPKMNPC1 | |
| SCHEMBL991362 | 0.81 | TSHR (0.50) | TSHRCES2LMNA | |
| SCHEMBL720572 | 0.81 | KDM4E (0.55) | TSHRCES2LMNA | |
| SCHEMBL24499264 | 0.80 | NCEH1 (0.43) | NCEH1RAB9ATSHRPKMNPC1 | |
| SCHEMBL17878567 | 0.80 | NCEH1 (0.47) | NCEH1RAB9ATSHRPKMNPC1 | |
| Hydrogen Peroxide SCHEMBL8008634 | 0.79 | KDM4E (0.58) | TSHRCES2LMNA | |
| SCHEMBL9979219 | 0.79 | TSHR (0.49) | TSHRCES2LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8470818-B2 | Compounds and methods for kinase modulation, and indications therefor | PLEXXIKON INC. (US) | 2013-06-25 | — | — | US | claimed |
| US-20100249118-A1 | protein kinase modulators such as Propane-1-sulfonic acid [2,4-difluoro-3-(5-ethoxy-1H-pyrrolo[1,3-b]pyridine-3-carbonyl)-phenyl]-amide, used to regulate signal transduction cascades, involved in the control of physiological functions including cellular growth and proliferation; anticarcinogenic agents | PLEXXIKON INC. | 2010-09-30 | — | — | US | claimed |
| US-20120122860-A1 | SOLID FORMS OF SULFONAMIDES AND AMINO ACIDS | PLEXXIKON, INC. | 2012-05-17 | — | — | US | disclosed |
| US-20120071475-A1 | UREA DERIVATIVES HAVING PI3K-INHIBITING ACTIVITY | SHIONOGI & CO., LTD. (JP) | 2012-03-22 | — | — | US | disclosed |
| US-20100286145-A1 | ISOPHTHALAMIDE DERIVATIVES INHIBITING BETA-SECRETASE ACTIVITY | COMENTIS, INC. (US) | 2010-11-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100249118-A1 | protein kinase modulators such as Propane-1-sulfonic acid [2,4-difluoro-3-(5-ethoxy-1H-pyrrolo[1,3-b]pyridine-3-carbonyl)-phenyl]-amide, used to regulate signal transduction cascades, involved in the control of physiological functions including cellular growth and proliferation; anticarcinogenic agents | MAP4K1, MAP4K2, MAP3K1 | NCEH1 3214/4885RAB9A 2228/4885TSHR 2257/4885 |
| US-20120122860-A1 | SOLID FORMS OF SULFONAMIDES AND AMINO ACIDS | BRAF, RAF1, ARAF | NCEH1 4297/4885RAB9A 1724/4885TSHR 2679/4885 |
| US-20100286145-A1 | ISOPHTHALAMIDE DERIVATIVES INHIBITING BETA-SECRETASE ACTIVITY | BACE1, BACE2, APP | NCEH1 27/4885RAB9A 3199/4885TSHR 4471/4885 |
| US-20120071475-A1 | UREA DERIVATIVES HAVING PI3K-INHIBITING ACTIVITY | MTOR, STAT3, SLC14A1 | NCEH1 638/4885RAB9A 1096/4885TSHR 3954/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.